Q-omics provides the consensus-scored OR10J6P profile across patient tissues and cancer cell-line models. OR10J6P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, OR10J6P is differentially expressed in 3, with the highest sampling consensus in LIHC. Additionally, OR10J6P RNA expression shows 7,378 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LUAD, LIHC, and KIRP as cancer lineages where OR10J6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR10J6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR10J6P survival associations across molecular data types. OR10J6P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR10J6P RNA expression–survival associations across cancer types. High OR10J6P expression shows unfavorable associations in LUAD, KICH, THCA, MESO and OV, but favorable associations in LIHC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for OR10J6P RNA expression.
This table summarizes OR10J6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for OR10J6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR10J6P shows lower tumor expression in LIHC, KICH and CHOL. The LIHC box plot shows higher OR10J6P RNA expression in normal versus tumor tissue (log2 FC = −0.934, t-test p = .001).
This table shows molecular features associated with OR10J6P in patient tissues and cancer cell lines. In patient samples, OR10J6P shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
